New drug cocktail shows promise for Tough-to-Treat leukemia in seniors

NCT ID NCT04230239

Completed Disease control Sponsor: PETHEMA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell transplant or maintenance therapy. The trial is now complete, and researchers are looking at remission rates and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX-351 (a combination of two chemotherapy drugs, daunorubicin and cytarabine, in a liposomal formulation)
What this could lead to: If successful, this could offer a more effective chemotherapy option for older adults with high-risk AML, potentially leading to better remission rates and disease control.
What could go wrong: This is a small, single-arm phase 2 trial with only 59 participants, so results may not apply to everyone. Chemotherapy carries significant side effects, and the study does not compare CPX-351 to other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEWLY DIAGNOSED SECONDARY OR HIGH RISK AML

Contacts and locations

Locations

Hospital Clínico Universitario de Valencia

Valencia, Spain
Hospital General Del H.U. Virgen Del Rocío

Seville, Spain
Hospital Ramón Y Cajal

Madrid, Spain
Hospital San Pedro de Alcántara

Cáceres, Spain
Hospital Universitario 12 de Octubre

Madrid, Spain
Hospital Universitario Central de Asturias

Oviedo, Spain
Hospital Universitario Lucus Augusti

Lugo, Spain
Hospital Universitario Reina Sofía

Córdoba, Spain
Hospital Universitario Y Politécnico La Fe

Valencia, Spain
Hospital Universitario de Gran Canaria Dr. Negrín

Las Palmas, Spain
Institut Català D'Oncologia - Hospital Duran I Reynals

Bellvitge, Spain
Institut Català D'Oncologia-Hospital Germans Trias I Pujol

Badalona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.